Global Information
회사소개 | 문의

인플루엔자 A(H7N9) 바이러스 감염증 : 파이프라인 리뷰

Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H1 2018

리서치사 Global Markets Direct
발행일 2018년 06월 상품 코드 410980
페이지 정보 영문 81 Pages
가격
US $ 2,000 ₩ 2,280,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,561,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,842,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


인플루엔자 A(H7N9) 바이러스 감염증 : 파이프라인 리뷰 Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H1 2018
발행일 : 2018년 06월 페이지 정보 : 영문 81 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

조류인플루엔자 A(H7N9)는 인플루엔자 바이러스의 아형이며, 이 감염증은 사람과 새 모두에게 감염됩니다. 사람이 감염된 집에서 기르는 새나 오염된 환경에 접촉했거나 노출되었을 경우에 감염됩니다. 증상은 열, 가래와 관련된 기침, 두통, 근육통, 전신권태감 등입니다. 치료에는 항바이러스제를 이용합니다.

인플루엔자 A(H7N9) 바이러스 감염증 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업 및 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트 관련 정보, 최신 뉴스와 발표 등을 전해드립니다.

서론

  • 조사 범위

인플루엔자 A(H7N9) 바이러스 감염증 개요

치료제 개발

  • 파이프라인 제품 : 개요
  • 파이프라인 제품 : 비교 분석

기업에서 개발중인 치료제

대학/연구기관에서 연구중인 치료제

파이프라인 제품 개요

  • 임상시험 단계 제품
  • 초기 단계 제품

기업에서 개발중인 제품

대학/연구기관에서 연구중인 제품

치료제 개발 참여 기업

  • EpiVax Inc
  • Fab'entech
  • Genentech Inc
  • GlaxoSmithKline Plc
  • Medigen Vaccine Biologics Corp
  • NanoViricides Inc
  • Visterra Inc
  • Vivaldi Biosciences Inc

치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

약제 프로파일

  • AT-501
  • FBF-002
  • GSK-3206640A
  • GSK-3206641A
  • influenza [strain A/H7N9] (monovalent) vaccine
  • influenza [strain A/H7N9] vaccine - Drug Profile
  • Monoclonal Antibody to Inhibit Hemagglutinin for Influenzavirus A Infections
  • NVINF-1
  • NVINF-2
  • Recombinant Protein to Target Sialic Acid Receptor for Influenza A Infections
  • VIS-410

부록

도표

LSH 17.01.31

List of Tables

  • Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by AusBio Ltd, H1 2018
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2018
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Cocrystal Pharma Inc, H1 2018
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by EpiVax Inc, H1 2018
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Genentech Inc, H1 2018
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by iBio Inc, H1 2018
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, H1 2018
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Medicago Inc, H1 2018
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Medigen Vaccine Biologics Corp, H1 2018
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Moderna Therapeutics Inc, H1 2018
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by NanoViricides Inc, H1 2018
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Ology Bioservices Inc, H1 2018
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Sanofi Pasteur SA, H1 2018
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Shionogi & Co Ltd, H1 2018
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by VirionHealth Ltd, H1 2018
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Visterra Inc, H1 2018
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Vivaldi Biosciences Inc, H1 2018
  • Influenza A Virus, H7N9 Subtype Infections - Dormant Projects, H1 2018

List of Figures

  • Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Targets, H1 2018
  • Number of Products by Stage and Targets, H1 2018
  • Number of Products by Mechanism of Actions, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Top 10 Molecule Types, H1 2018
  • Number of Products by Stage and Top 10 Molecule Types, H1 2018

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H1 2018, provides an overview of the Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline landscape.

Avian influenza A (H7N9) is a subtype of influenza viruses. This infection is seen both in humans and birds. Infection is caused when a person is exposure to infected poultry or contaminated environments. Symptoms include fever, cough that produces sputum, headache, myalgia and general malaise. Treatment includes antiviral drugs

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H7N9 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 6, 13 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 4 molecules, respectively.

Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H7N9 Subtype Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Influenza A Virus, H7N9 Subtype Infections - Overview
    • Influenza A Virus, H7N9 Subtype Infections - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Influenza A Virus, H7N9 Subtype Infections - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Influenza A Virus, H7N9 Subtype Infections - Companies Involved in Therapeutics Development
    • AusBio Ltd
    • Beijing Minhai Biotechnology Co Ltd
    • Cocrystal Pharma Inc
    • EpiVax Inc
    • Genentech Inc
    • iBio Inc
    • Inovio Pharmaceuticals Inc
    • Medicago Inc
    • Medigen Vaccine Biologics Corp
    • Moderna Therapeutics Inc
    • NanoViricides Inc
    • Ology Bioservices Inc
    • Sanofi Pasteur SA
    • Shionogi & Co Ltd
    • VirionHealth Ltd
    • Visterra Inc
    • Vivaldi Biosciences Inc
  • Influenza A Virus, H7N9 Subtype Infections - Drug Profiles
    • AT-501 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • baloxavir marboxil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CC-42344 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H7N9] (monovalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H7N9] (monovalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H7N9] (monovalent) vaccine 1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H7N9] (monovalent) vaccine 2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H7N9] (split virion) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H7N9] (whole virion) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H7N9] (whole virion) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H7N9] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H7N9] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H7N9] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H7N9] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H7N9] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H7N9] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H7N9] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H7N9] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H7N9] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MD-2009 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit Hemagglutinin for Influenza Virus A Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mRNA-1851 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MT-7529 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NVINF-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NVINF-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Target Sialic Acid Receptor for Influenza A Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Neuraminidase A for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VB-126LAIV - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VH-244 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VIS-410 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Influenza A Virus, H7N9 Subtype Infections - Dormant Projects
  • Influenza A Virus, H7N9 Subtype Infections - Product Development Milestones
    • Featured News & Press Releases
      • Sep 08, 2017: Shionogi to Present New Data on S-033188, a Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, at the 6th European Scientific Working Group in Influenza Conference
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
전화 문의
이용안내
 
BCC Research